Predict your next investment

EDP Biotech company logo
Private
HEALTHCARE | Medical Devices & Equipment / Other Medical Devices
edpbiotech.com

See what CB Insights has to offer

Founded Year

2005

Stage

Unattributed - V | Alive

Total Raised

$3.83M

About EDP Biotech

EDP Biotech Corporation is a privately held medical device company focused on the development and commercialization of blood-based immunodiagnostic assays.

EDP Biotech Headquarter Location

6701 Baum Drive Suite 110

Knoxville, Tennessee, 37919,

United States

865-299-6250

Latest EDP Biotech News

EDP Biotech secures investment capital from Sheltowee’s two funds and High Country Impact Fund

May 14, 2021

on May 13 th, 2021 By Tom Ballard, Chief Alliance Officer, PYA It’s always good news when we can end a week with a report on a local company that has secured investment capital, and it’s even better when the lead investor is a Knoxville-based fund manager. Two parts of the Sheltowee organization – the Sheltowee Angel Network and the Sheltowee Medical Device Fund LP – have joined with the High Country Impact Fund from Boone, NC to make a substantial investment in EDP Biotech Corporation , the Knoxville-based entity founded by Tom Boyd. The exact amount was not disclosed. “This validates what we are doing,” said Eric Mayer, EDP Biotech’s Chief Executive Officer (CEO). “These are real venture investors in the life science sector.” Regular readers of teknovation.biz have followed the company over the past several years (click here for the many articles) as it has worked to prepare for the commercialization of ColoPlex™, an inexpensive blood test that accurately detects early stage colorectal cancer and pre-cancerous polyps at the stage where such early detection leads to the best patient outcomes. When COVID-19 hit, the company began exploring ways to use its lab facilities on Baum Drive in West Knoxville to fill a void and by July had been approved as a testing lab for the detection of human antibodies to the SARS-CoV-2 S1 protein, SARS-CoV-2 S2 protein, a negative control (Sheep Fc), and a positive control (anti-human IgG). “This convertible note will help us in several ways,” Mayer said. One will be funding to continue the data analysis that must be undertaken ahead of the commercialization of the ColoPlex™ product; the other is to continue growing EDP Biotech’s clinical testing operation, including work for other businesses like clinical research organizations. “We have followed the company’s progress for several years and decided to move forward simply because of the ‘never-say-die’ team with great technology and commercial potential,” said Dobson, CEO of Sheltowee Angel Network and Managing Partner of the Sheltowee Medical Device Fund. “They just keep finding ways of creating value even under the toughest of circumstances. This is an important technology that needs to reach the market. A lot of lives can be saved by its use.” Both Mayer and Dobson underscored the significance of the leadership for the investment coming from a local fund and how that investment will help keep the company here rather than having to “follow the money” to one of the coasts. “EDP Biotech stands to make a huge impact on the medial industry and society,” Dobson said. “It is clear they have been good stewards of resources and have a clear commercialization plan.” As described in this teknovation.biz article from March 2020 , Sheltowee Angel Network was created by a merger of the former Angel Capital Group, which Dobson headed, and the Sheltowee Business Network. Late last year, the Sheltowee Angel Network joined with the DeltaForce Group from Charlotte, NC to form the Sheltowee Medical Device Fund, making its first investment in EMBolic Acceleration LLC (see teknovation.biz article here .)

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EDP Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EDP Biotech is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,869 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

EDP Biotech Patents

EDP Biotech has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Gastrointestinal cancer
  • Infectious causes of cancer
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/29/2014

9/5/2017

Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/29/2014

00/00/0000

Grant Date

9/5/2017

00/00/0000

Title

Subscribe to see more

Related Topics

Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Proteins

Subscribe to see more

Status

Grant

Subscribe to see more

EDP Biotech Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EDP Biotech Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.